在癌症患者中探索HALP得分和死亡率之间的J形关系:NHANES 1999-2018年队列研究
Jiaxing Dong1, Wanju Jiang1, Wenjia Zhang2
1Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Frontiers in oncology
|September 20, 2024
概括
血红蛋白,白蛋白,淋巴细胞和血小板 (HALP) 评分与癌症患者的长期死亡率降低有关. 这项研究揭示了较高的HALP得分和改善的生存结果之间存在显著的非线性关联.
科学领域:
- 在瘤学瘤学.
- 临床营养学 临床营养学
- 生物统计学 生物统计学
背景情况:
- 血红蛋白,白蛋白,淋巴细胞和血小板 (HALP) 评分评估患者的营养和免疫状态.
- 以前的研究表明,HALP得分和癌症预后之间存在正相关性.
- 有关影响HALP分数临床应用的混因素存在担忧.
研究的目的:
- 研究癌症患者的HALP得分和长期死亡率之间的关联.
- 探索潜在的非线性关系,并确认各种癌症类型的发现.
主要方法:
- 利用了来自国家健康和营养检查调查 (NHANES) 的3832名癌症患者的数据.
- 采用COX回归和限制立方线 (RCS) 曲线来分析HALP得分和死亡风险之间的关系.
- 进行了Kaplan-Meier (K-M) 生存分析和子组分析以验证.
主要成果:
- 较高的HALP得分与癌症患者长期死亡风险降低有关.
- 确定了HALP得分与死亡风险之间的非线性关联.
- 结果在各个子组分析和特定癌症类型中一致,包括乳腺,结直肠,子宫,子宫,黑色素瘤,前列腺和皮肤癌.
结论:
- 哈尔普得分是癌症患者长期死亡率的独立预测指标.
- 存在一种非线性关系,突出显示HALP得分对生存的微妙影响.
- 结果为癌症护理中的临床和营养干预提供了新的见解.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
223
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
相关概念视频
Cancer Survival Analysis
331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331
Comparing the Survival Analysis of Two or More Groups
158
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
158
Hazard Ratio
92
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
92
Actuarial Approach
64
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
64
Hazard Rate
92
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
92
Kaplan-Meier Approach
107
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
107
